{"sequenceId":"845362138137","id":"34207109332","language":"English","title":"Contrasting Nexa Resources (NEXA) and Opiant Pharmaceuticals (OPNT)","content":"Nexa Resources (NYSE: NEXA) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.    Valuation and Earnings         This table compares Nexa Resources and Opiant Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.    Gross Revenue  Price/Sales Ratio  Net Income  Earnings Per Share  Price/Earnings Ratio  Nexa Resources  $2.45 billion  0.86  $126.88 million  $1.42  11.16  Opiant Pharmaceuticals  $18.45 million  2.27  $6.58 million  $2.94  5.51   Nexa Resources has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Nexa Resources, indicating that it is currently the more affordable of the two stocks.  Profitability    This table compares Nexa Resources and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.    Net Margins  Return on Equity  Return on Assets  Nexa Resources  6.37%  5.78%  2.81%  Opiant Pharmaceuticals  -379.64%  -574.62%  -203.65%   Analyst Ratings    This is a breakdown of recent recommendations for Nexa Resources and Opiant Pharmaceuticals, as provided by MarketBeat.    Sell Ratings  Hold Ratings  Buy Ratings  Strong Buy Ratings  Rating Score  Nexa Resources  0  0  6  0  3.00  Opiant Pharmaceuticals  0  0  0  0  N/A   Nexa Resources currently has a consensus price target of $22.52, indicating a potential upside of 42.06%. Given Nexa Resources’  higher possible upside, equities research analysts clearly believe Nexa Resources is more favorable than Opiant Pharmaceuticals.    Insider & Institutional Ownership    13.4% of Nexa Resources shares are held by institutional investors. Comparatively, 4.3% of Opiant Pharmaceuticals shares are held by institutional investors. 63.8% of Opiant Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.    Dividends    Nexa Resources pays an annual dividend of $0.47 per share and has a dividend yield of 3.0%. Opiant Pharmaceuticals does not pay a dividend. Nexa Resources pays out 33.1% of its earnings in the form of a dividend.    Summary    Nexa Resources beats Opiant Pharmaceuticals on 10 of the 14 factors compared between the two stocks.    Nexa Resources Company Profile    Nexa Resources S.A., through its subsidiaries, primarily produces, refines, processes, and sells zinc in Peru and Brazil. It explores, extracts, produces, and trades zinc, copper, and lead concentrates through its mining sites located in the regions of Pasco, Ica, and Moquegua in Peru. The company also has copper mining project located in the Conchucos District, Ancash Region; poly-metallic mining project located in the Ancash Region; and copper mining project located in the Huancavelica Region, as well as zinc mines in Vazante and Paracatu. In addition, it refines byproducts, such as sulfuric acid, copper, and silver. The company serves chemical, petrochemical, rubber, pulp, metallurgy, mining, agricultural, and other sectors; and exports its zinc to Europe and the Americas. The company was formerly known as VM Holding S.A. and changed its name to Nexa Resources S.A. in September 2017. The company was founded in 1956 and is headquartered in Luxembourg City, Luxembourg. Nexa Resources S.A. is a subsidiary of Votorantim S.A.    Opiant Pharmaceuticals Company Profile    Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.","contentWithMarkup":"Nexa Resources (NYSE: NEXA) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both basic materials companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.    Valuation and Earnings         This table compares Nexa Resources and Opiant Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.    Gross Revenue  Price/Sales Ratio  Net Income  Earnings Per Share  Price/Earnings Ratio  Nexa Resources  $2.45 billion  0.86  $126.88 million  $1.42  11.16  Opiant Pharmaceuticals  $18.45 million  2.27  $6.58 million  $2.94  5.51   Nexa Resources has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than Nexa Resources, indicating that it is currently the more affordable of the two stocks.  Profitability    This table compares Nexa Resources and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.    Net Margins  Return on Equity  Return on Assets  Nexa Resources  6.37%  5.78%  2.81%  Opiant Pharmaceuticals  -379.64%  -574.62%  -203.65%   Analyst Ratings    This is a breakdown of recent recommendations for Nexa Resources and Opiant Pharmaceuticals, as provided by MarketBeat.    Sell Ratings  Hold Ratings  Buy Ratings  Strong Buy Ratings  Rating Score  Nexa Resources  0  0  6  0  3.00  Opiant Pharmaceuticals  0  0  0  0  N/A   Nexa Resources currently has a consensus price target of $22.52, indicating a potential upside of 42.06%. Given Nexa Resources’  higher possible upside, equities research analysts clearly believe Nexa Resources is more favorable than Opiant Pharmaceuticals.    Insider & Institutional Ownership    13.4% of Nexa Resources shares are held by institutional investors. Comparatively, 4.3% of Opiant Pharmaceuticals shares are held by institutional investors. 63.8% of Opiant Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.    Dividends    Nexa Resources pays an annual dividend of $0.47 per share and has a dividend yield of 3.0%. Opiant Pharmaceuticals does not pay a dividend. Nexa Resources pays out 33.1% of its earnings in the form of a dividend.    Summary    Nexa Resources beats Opiant Pharmaceuticals on 10 of the 14 factors compared between the two stocks.    Nexa Resources Company Profile    Nexa Resources S.A., through its subsidiaries, primarily produces, refines, processes, and sells zinc in Peru and Brazil. It explores, extracts, produces, and trades zinc, copper, and lead concentrates through its mining sites located in the regions of Pasco, Ica, and Moquegua in Peru. The company also has copper mining project located in the Conchucos District, Ancash Region; poly-metallic mining project located in the Ancash Region; and copper mining project located in the Huancavelica Region, as well as zinc mines in Vazante and Paracatu. In addition, it refines byproducts, such as sulfuric acid, copper, and silver. The company serves chemical, petrochemical, rubber, pulp, metallurgy, mining, agricultural, and other sectors; and exports its zinc to Europe and the Americas. The company was formerly known as VM Holding S.A. and changed its name to Nexa Resources S.A. in September 2017. The company was founded in 1956 and is headquartered in Luxembourg City, Luxembourg. Nexa Resources S.A. is a subsidiary of Votorantim S.A.    Opiant Pharmaceuticals Company Profile    Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.","tags":[],"publishedDate":"2018-06-02T16:22:55Z","harvestDate":"2018-06-02T21:23:59Z","estimatedPublishedDate":"2018-06-02T16:22:55Z","url":"http://ct.moreover.com/?a=34207109332&p=1u0&v=1&x=gHrWthpTaGBQQSLX4AoIFw","originalUrl":"https://www.com-unik.info/2018/06/02/contrasting-nexa-resources-nexa-and-opiant-pharmaceuticals-opnt.html","outboundUrls":[],"wordCount":"624","dataFormat":"text","duplicateGroupId":"34207109332","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Pharma industry news","group":"Industry"},{"name":"Finance latest","group":"Finance"}],"companies":[{"name":"Opiant Pharmaceuticals Inc","symbol":"OPNT","exchange":"NAS","isin":"US6837501039","titleCount":1,"contentCount":21,"primary":true},{"name":"Opiant Pharmaceuticals Inc","symbol":"8OP","exchange":"STU","isin":"US6837501039","titleCount":1,"contentCount":21,"primary":true},{"name":"Nexa Resources SA","symbol":"NEXA","exchange":"NYS","isin":"LU1701428291","titleCount":1,"contentCount":20,"primary":false},{"name":"Nexa Resources SA","symbol":"NEXA","exchange":"TSE","isin":"LU1701428291","titleCount":1,"contentCount":20,"primary":false},{"name":"Nexa Resources SA","symbol":"NE0","exchange":"FRA","isin":"LU1701428291","titleCount":1,"contentCount":20,"primary":false},{"name":"Nexa Resources SA","symbol":"NEO","exchange":"BER","isin":"LU1701428291","titleCount":1,"contentCount":20,"primary":false},{"name":"GMR Materials Co Ltd","symbol":"032860","exchange":"KRX","isin":"KR7032860009","titleCount":0,"contentCount":1,"primary":false},{"name":"Lead Co Inc","symbol":"6982","exchange":"TKS","isin":"JP3969400005","titleCount":0,"contentCount":1,"primary":false},{"name":"Titan Pharmaceuticals Inc","symbol":"TN71","exchange":"BER","isin":"US8883143096","titleCount":0,"contentCount":1,"primary":false},{"name":"Titan Pharmaceuticals Inc","symbol":"TTNP","exchange":"NAS","isin":"US8883143096","titleCount":0,"contentCount":1,"primary":false},{"name":"Titan Pharmaceuticals Inc","symbol":"TN71","exchange":"FRA","isin":"US8883143096","titleCount":0,"contentCount":1,"primary":false},{"name":"Titan Pharmaceuticals Inc","symbol":"TN71","exchange":"STU","isin":"US8883143096","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Cynthia Vaughn","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Community Financial News","homeUrl":"https://www.com-unik.info","category":"Trade","editorialRank":"5","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"637628019","name":"Community Financial News","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"0"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Financials"],"genre":"General"}},"es_id":86990252}